Harvard IPO no-no
This article was originally published in Clinica
Just two weeks after announcing plans to spin-off and float its Harvard Apparatus Regenerative Technology (HART), Harvard Bioscience has postponed the IPO due to “market conditions”. The company had been hoping to sell 1.7 million HART shares priced at $10-12 each to raise around $18.7 million (www.clinica.co.uk, 27 March 2013). HART makes synthetic organs for implantation from patients’ own stem cells, with an initial focus on the trachea.